Get started
Work

CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma

Year: 2024
Type: article
Study design: Case Report
Abstract: Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is highly effective in B-cell blood cancers, but there is limited data on its safety and efficacy in intra-cardiac lymphoma, due to the potential risks of cardiotoxicity and pseudo-progression. Discussion: We discuss four high-risk cases that were managed with a multi-disciplinary approach, including baseline cardiac risk assessment and surveillance with multimodal cardiac imaging and serum cardiac biomarkers, elective supportive care in the intensive care unit, and early treatment of cytokine release syndrome. Conclusion: CAR-T therapy can be effective and safe in the treatment of B-cell blood cancers with intra-cardiac disease.
Source: eJHaem
DOI: 10.1002/jha2.1020
Authors: Daniel H. Chen, Maeve O'Reilly, Kathleen P. Cheok, Ryan Low, Rajesh Puranik, Samuel Clark, John Malcolm Walker, Charlotte Manisty, Arjun K. Ghosh, Claire Roddie
Institutions: University College Hospital, University College London Hospitals NHS Foundation Trust, University College London, The University of Sydney, Royal Prince Alfred Hospital, St Bartholomew's Hospital, Barts Health NHS Trust
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,600
OpenAlex ID: W4403513159
FWCI: 0.306
Cites: 15
Cited by: 2
Related to: 10